Telix Pharmaceuticals Limited’s Gross Margin at a glance
Telix Pharmaceuticals Limited reports gross margin of 65.1% for Dec 2024. The prior period recorded 62.6% (Dec 2023). Year over year the metric moved +2.5 pts (+4%). The rolling three-period average stands at 48.7%. Data last refreshed Dec 7, 2025, 2:46 AM.
Latest reading
65.1% · Dec 2024
YoY movement
+2.5 pts (+4%)
Rolling average
48.7%
Current Gross Margin
65.1%
+2.5 pts
+4%
Rolling average
48.7%
Latest Value
65.1%
Dec 2024
YoY Change
+2.5 pts
Absolute
YoY Change %
+4%
Rate of change
3-Period Avg
48.7%
Smoothed
Narrative signal
Telix Pharmaceuticals Limited’s gross margin stands at 65.1% for Dec 2024. Year-over-year, the metric shifted by +2.5 pts, translating into a +4% rate of change versus the prior period.
Pair this momentum with product cadence, pricing power, and capital allocation moves to understand durability.
Blend with balance sheet, cash flow, and peer benchmarks from AlphaPilot’s broader dashboards to shape an investable thesis.
How gross margin shapes Telix Pharmaceuticals Limited's story
As of Dec 2024, Telix Pharmaceuticals Limited reports gross margin of 65.1%. Measure pricing power and cost of goods efficiency by reviewing historical gross margins.
Pricing versus input costs
Gross margin expands when pricing power or mix more than offset raw material and labor inflation.
Benchmark to peers
Compare margins within a sector to spot operational advantages or signs of discounting.
Valuation Multiples
Compare how the market prices revenue, equity, and operating cash flow versus peers and history.
Profitability & Margins
Understand cost structure and capital efficiency trends across gross, operating, and net results.
Growth Momentum
Track whether top-line, earnings, and free cash flow growth are accelerating or cooling.
Balance Sheet Strength
Evaluate leverage, liquidity, and cash generation capacity that underpin resilience.
Shareholder Returns
Follow dividend sustainability and cash generation relative to market value.
Telix Pharmaceuticals Limited (TLX) FAQs
Answers tailored to Telix Pharmaceuticals Limited’s gross margin profile using the latest Financial Modeling Prep data.
What is Telix Pharmaceuticals Limited's current gross margin?
As of Dec 2024, Telix Pharmaceuticals Limited reports gross margin of 65.1%. This reading reflects the latest filings and price data for TLX.
How is Telix Pharmaceuticals Limited's gross margin trending year over year?
Year-over-year, the figure shifts by +2.5 pts (+4%). Pair this context with revenue growth and free cash flow signals to gauge momentum for TLX.
Why does gross margin matter for Telix Pharmaceuticals Limited?
Gross margin tracks the percentage of revenue remaining after direct production and service delivery costs. For Telix Pharmaceuticals Limited, operating within Healthcare — Biotechnology, tracking this metric helps benchmark management's execution against close competitors.
Is Telix Pharmaceuticals Limited's gross margin above its recent average?
Telix Pharmaceuticals Limited's rolling three-period average sits at 48.7%. Comparing the latest reading of 65.1% to that baseline highlights whether momentum is building or fading for TLX.
How frequently is Telix Pharmaceuticals Limited's gross margin refreshed?
Data for TLX was last refreshed on Dec 7, 2025, 2:46 AM and updates automatically every 24 hours, keeping your valuation inputs current.